InspireMD (NSPR)
NASDAQ:NSPR
Top Page
InspireMD
(NASDAQ:NSPR)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▼(-18.48% Downside)
Action:ReiteratedDate:03/19/26
The score is held down mainly by weak financial quality—large operating losses and materially negative cash flow despite revenue growth and improving margins. Technicals are mixed (minor near-term improvement but still below longer-term averages), valuation support is limited based on the provided P/E and lack of dividend yield, while the earnings call adds a modest positive tilt due to U.S. launch-driven growth and guidance despite higher spending and ongoing losses.
Positive Factors
U.S. Commercial Launch / FDA Approval
FDA clearance and the commercial rollout of CGuard Prime establish a durable expansion into the U.S. market, materially enlarging the addressable market and diversifying revenue sources. Sustained U.S. adoption supports long-term sales growth and clinical validation aiding payer and physician uptake.
Negative Factors
Deep Negative Operating and Free Cash Flow
Persistently and increasingly negative operating and free cash flow indicate the business does not yet generate cash from operations, creating structural dependence on external financing. Over months to years this raises execution and dilution risk if commercial ramp or trial timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
U.S. Commercial Launch / FDA Approval
FDA clearance and the commercial rollout of CGuard Prime establish a durable expansion into the U.S. market, materially enlarging the addressable market and diversifying revenue sources. Sustained U.S. adoption supports long-term sales growth and clinical validation aiding payer and physician uptake.
Read all positive factors
InspireMD (NSPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$62.71M
Dividend YieldN/A
Average Volume (3M)102.59K
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue Growth14.04%
EPS Growth-0.65%
CountryUS
Employees85
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.14
Shares Outstanding46,801,560
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue6.24
Enterprise Value/Gross Profit21.14
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$5.50Price Target Upside198.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$14.55M
InspireMD Business Overview & Revenue Model
Company Description
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia P...
How the Company Makes Money
InspireMD’s primary monetization model is selling its medical device products (carotid stent systems and related accessories, if applicable) to healthcare providers and/or through distribution channels, generating revenue when products are purchas...
InspireMD Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down where the company earns sales across countries and regions, showing which markets drive current revenue. For a small medical-device firm like InspireMD, geographic concentration highlights dependence on a few markets, distributors, or regulatory approvals, while expansion into new regions points to commercial traction and growth potential. Also signals exposure to currency moves, local reimbursement and healthcare funding, and where future upside or downside is most likely to occur.
Breaks down where the company earns sales across countries and regions, showing which markets drive current revenue. For a small medical-device firm like InspireMD, geographic concentration highlights dependence on a few markets, distributors, or regulatory approvals, while expansion into new regions points to commercial traction and growth potential. Also signals exposure to currency moves, local reimbursement and healthcare funding, and where future upside or downside is most likely to occur.
Data provided by:
The Fly
The FlyInspireMD Earnings Call Summary
Earnings Call Date:Nov 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth driven by the successful launch of CGuard Prime in the U.S. and strong international performance. Financially, the company showed improved gross margins and a strengthened cash position due to successful financing. However, increased operating expenses and a higher net loss were noted as challenges. Overall, the positive achievements and growth prospects outweighed the financial challenges.Positive Updates
Significant Revenue Growth
InspireMD's total revenue for the third quarter of 2025 reached $2.5 million, representing a year-over-year growth of 39% and sequential growth of over 40% since the last quarter.
Negative Updates
Increase in Operating Expenses
Total operating expenses for the third quarter of 2025 were $13.9 million, an increase of 57% compared to the third quarter of 2024, primarily due to higher headcount-related expenses and infrastructure costs.
Read all updates
Q3-2025 Updates
Positive
Negative
Significant Revenue Growth
InspireMD's total revenue for the third quarter of 2025 reached $2.5 million, representing a year-over-year growth of 39% and sequential growth of over 40% since the last quarter.
Read all positive updates
Company Guidance
During the InspireMD Third Quarter 2025 Earnings Conference Call, the company reported a total revenue of $2.5 million, marking a 39% year-over-year increase and over 40% sequential growth from the previous quarter. This growth was driven by the strong initial U.S. launch of the CGuard Prime carotid stent, following FDA approval in late June, and steady international demand. U.S. revenue for the quarter reached $497,000, while international revenue was $2.0 million, an increase of 12% from the previous year. Gross profit more than doubled to $864,000, with a gross margin of 34.2%, up from 22.9% the previous year. The company reported a net loss of $12.7 million or $0.17 per share. As of September 30, 2025, cash and cash equivalents stood at $63.4 million, bolstered by recent financing events. Looking ahead, InspireMD anticipates fourth-quarter revenue between $2.5 million and $3.0 million, with continuous growth expected from U.S. sales and consistent international demand.InspireMD Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.98M | 7.01M | 6.21M | 5.17M | 4.50M |
| Gross Profit | 2.65M | 1.51M | 1.81M | 1.12M | 754.00K |
| EBITDA | -48.64M | -33.22M | -20.91M | -18.52M | -14.55M |
| Net Income | -48.79M | -32.01M | -19.92M | -18.49M | -14.92M |
Balance Sheet | |||||
| Total Assets | 69.40M | 46.81M | 47.64M | 24.65M | 39.71M |
| Cash, Cash Equivalents and Short-Term Investments | 54.21M | 34.64M | 39.02M | 17.80M | 34.04M |
| Total Debt | 2.22M | 2.34M | 1.59M | 1.61M | 1.20M |
| Total Liabilities | 14.20M | 10.72M | 8.14M | 7.26M | 6.18M |
| Stockholders Equity | 55.20M | 36.09M | 39.50M | 17.39M | 33.53M |
Cash Flow | |||||
| Free Cash Flow | -36.77M | -23.27M | -16.76M | -16.02M | -13.55M |
| Operating Cash Flow | -35.10M | -21.87M | -16.38M | -15.54M | -13.21M |
| Investing Cash Flow | -30.56M | 12.64M | -16.09M | 8.44M | -22.46M |
| Financing Cash Flow | 55.57M | 18.45M | 37.53M | -140.00K | 35.03M |
InspireMD Technical Analysis
Negative
1.84
Price Trends
1.68
Negative
1.77
Negative
2.07
Negative
Market Momentum
-0.07
Positive
28.93
Positive
7.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Negative. The current price of 1.84 is above the 20-day moving average (MA) of 1.64, above the 50-day MA of 1.68, and below the 200-day MA of 2.07, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 28.93 is Positive, neither overbought nor oversold. The STOCH value of 7.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NSPR.
InspireMD Risk Analysis
InspireMD disclosed 40 risk factors in its most recent earnings report. InspireMD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InspireMD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $66.50M | 22.00 | 10.27% | ― | 16.88% | ― | |
60 Neutral | $203.96M | -12.67 | -7.42% | ― | -31.29% | 65.68% | |
52 Neutral | $167.32M | -13.16 | -117.54% | ― | -1.32% | 55.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $125.94M | -4.20 | -111.74% | ― | ― | ― | |
49 Neutral | $62.71M | -2.78 | -116.22% | ― | 14.04% | -0.65% | |
44 Neutral | $88.03M | -2.88 | -317.03% | ― | ― | -0.27% |
* Healthcare Sector Average
NSPR
InspireMD
1.34
-1.32
-49.62%
ANIK
Anika Therapeutics
15.22
1.62
11.91%
APYX
Apyx Medical
4.00
3.12
354.55%
EDAP
EDAP TMS
3.36
1.91
131.72%
VANI
Vivani Medical
1.04
0.03
2.97%
XTNT
Xtant Medical Holdings
0.47
0.09
24.74%
InspireMD Corporate Events
Business Operations and StrategyPrivate Placements and Financing
InspireMD Establishes New $75 Million ATM Program
Neutral
Apr 3, 2026
On April 3, 2026, InspireMD entered into a new Equity Distribution Agreement with BTIG, LLC to potentially sell up to $75 million of its common stock through at-the-market and negotiated transactions under an existing shelf registration. BTIG will...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
InspireMD Reports Strong Q4 2025 Growth and Expansion
Positive
Mar 18, 2026
InspireMD, Inc., a developer of the CGuard Prime carotid stent system for stroke prevention, reported fourth quarter and full-year 2025 results on March 18, 2026, highlighting strong top-line growth driven by its U.S. launch and expanding internat...
Business Operations and StrategyExecutive/Board Changes
InspireMD Announces Planned Departure of Chief Operating Officer
Negative
Mar 4, 2026
On February 27, 2026, InspireMD, Inc. issued a dismissal notice to Chief Operating Officer Andrea Tommasoli, who has been employed under a French law-governed contract with its subsidiary since November 2, 2020. His employment termination is subje...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.